Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PREDNISONE vs ACTICORT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Agonist at glucocorticoid receptors, leading to altered gene transcription that results in anti-inflammatory and immunosuppressive effects, including suppression of cytokines, prostaglandins, and leukotrienes.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production and inflammatory mediators via glucocorticoid receptor binding.
Allergic reactions (severe or incapacitating),Asthma,Chronic obstructive pulmonary disease (COPD) exacerbation,Collagen diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis),Dermatologic diseases (e.g., pemphigus, severe erythema multiforme),Endocrine disorders (e.g., adrenocortical insufficiency, congenital adrenal hyperplasia),Gastrointestinal diseases (e.g., ulcerative colitis, Crohn's disease),Hematologic disorders (e.g., autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura),Neoplastic diseases (e.g., leukemias, lymphomas),Nephrotic syndrome,Ophthalmic diseases (e.g., severe allergic conjunctivitis, keratitis),Organ transplantation (immunosuppression),Respiratory diseases (e.g., sarcoidosis, berylliosis),Rheumatic disorders (e.g., acute gouty arthritis, psoriatic arthritis),Tuberculous meningitis (with appropriate antituberculous therapy)
Corticosteroid-responsive dermatoses (e.g., eczema, psoriasis, contact dermatitis),Off-label: atopic dermatitis, lichen planus, discoid lupus erythematosus
5-60 mg orally once daily or divided twice daily; for acute indications, initial dose 5-60 mg/day; for chronic conditions, lowest effective dose; route: oral, intravenous, intramuscular.
5-60 mg orally once daily, or divided twice daily, depending on condition severity and response.
Terminal half-life: 2-3 hours (plasma); clinical effects persist for 12-36 hours due to intracellular actions and active metabolite prednisolone (half-life 3-4 hours).
1.5-2.5 hours; prolonged in hepatic impairment (up to 10 hours) and renal impairment (up to 6 hours)
Hepatic, primarily via CYP3A4-mediated 6β-hydroxylation; also reduced by 20-ketosteroid reductases. Prednisone is a prodrug converted to active metabolite prednisolone.
Hepatic metabolism via CYP3A4; inactive metabolites excreted renally and biliary.
Renal: <10% as unchanged drug; hepatic metabolism to inactive glucuronide and sulfate conjugates; fecal: ~20-30% via biliary elimination.
Renal (70% as unchanged drug and metabolites), biliary/fecal (30%)
Prednisone: 70-90% bound to albumin and corticosteroid-binding globulin (CBG); prednisolone: 60-70% bound.
90% bound to albumin and corticosteroid-binding globulin
Vd: 0.5-1.0 L/kg; distributes widely, crosses placenta and enters breast milk; apparent Vd larger with hyperthyroidism.
1.2-1.5 L/kg; indicates extensive tissue distribution
Oral: 70-80% (active prednisolone after hepatic conversion); IM: ~100%.
Oral: 80-90%; IM: 100%
No dose adjustment required for renal impairment; consider alternative corticosteroid in severe renal disease if fluid retention is a concern.
No dose adjustment necessary for acute use; for chronic therapy in severe renal impairment (e GFR <30 m L/min/1.73 m2), consider dose reduction by 50% to minimize mineralocorticoid effects.
Child-Pugh A: no adjustment. Child-Pugh B or C: use with caution; dose reduction may be considered due to decreased clearance; monitor for adverse effects.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75% due to reduced clearance.
0.1-2 mg/kg/day orally divided 1-4 times daily; maximum 60 mg/day; use lowest effective dose; for acute asthma, 1-2 mg/kg/day for 3-5 days.
0.05-2 mg/kg/day orally divided every 6-8 hours, not to exceed 80 mg/day; adjust based on response and severity.
Start at lower end of dosing range (5-7.5 mg/day) due to increased risk of osteoporosis, hyperglycemia, and infections; monitor glucose and bone density; taper slowly to avoid adrenal suppression.
Initiate at lowest effective dose (e.g., 5 mg/day) and titrate slowly due to increased risk of osteoporosis, glucose intolerance, and immunosuppression; monitor for adverse effects.
None
None
Adrenal suppression and HPA axis suppression with prolonged therapy,Increased risk of infections,Exacerbation of systemic fungal infections,Masking of signs of infection,Osteoporosis with long-term use,Gastrointestinal perforation (especially in patients with certain GI disorders),Kaposi sarcoma reported,Cardiovascular effects (hypertension, fluid retention),Behavioral disturbances (euphoria, depression, psychosis),Posterior subcapsular cataracts and glaucoma,Thromboembolism risk,Vaccine response may be diminished; live vaccines contraindicated
HPA axis suppression with prolonged use or large surface area,Local irritation and skin atrophy,Systemic absorption with occlusive dressings,Potential for rebound effects after discontinuation
Systemic fungal infections,Hypersensitivity to prednisone or any component,Administration of live or live attenuated vaccines (due to immunosuppression)
Known hypersensitivity to components,Untreated bacterial/fungal infections,Viral skin infections (e.g., herpes simplex, varicella),Perioral dermatitis, rosacea
Avoid grapefruit juice as it may increase prednisone levels. Limit high-sodium foods to prevent fluid retention. Increase calcium and vitamin D intake to counteract bone loss. Avoid alcohol due to added GI irritation risk.
No clinically significant food interactions. Alcohol may increase systemic absorption if tympanic membrane is perforated, but generally avoid alcohol-based ear drops if perforation suspected.
First trimester: Increased risk of cleft lip/palate (odds ratio 1.3-3.4). Second/third trimester: Fetal growth restriction, adrenal suppression, preterm delivery. Chronic use: Dose-dependent fetal hypothalamic-pituitary-adrenal axis suppression.
First trimester: Increased risk of cleft palate and cardiac defects (OR 1.3-3.5). Second/third trimesters: Risk of fetal growth restriction, adrenal suppression, and oligohydramnios with chronic use. Avoid use unless maternal benefit outweighs risks.
Prednisone enters breast milk in low concentrations (M/P ratio ~0.25-0.5). Maternal doses ≤20 mg/day produce negligible infant exposure. Higher doses: Avoid breastfeeding for 4 hours after dose. Monitor infant for growth and adrenal suppression.
Prednisone enters breast milk at low levels (M/P ratio ~0.1-0.3). At maternal doses ≤20 mg/day, the infant dose is <10% of maternal weight-adjusted dose. Consider risk of adrenal suppression in infant with high-dose, long-term therapy. AAP rates as compatible with breastfeeding.
Minimal pharmacokinetic changes (slight increase in clearance). No routine dose adjustment needed. For acute indications, use lowest effective dose. For chronic conditions, increase dose may be needed in third trimester due to disease flare; taper postpartum.
No empirical dose adjustment required; however, pharmacokinetic changes (increased Vd, hepatic metabolism) may reduce efficacy. Doses may need to be increased by 20-30% in third trimester if disease activity increases. Taper to lowest effective dose.
Prednisone is a prodrug converted to prednisolone; use prednisolone in severe hepatic impairment. Taper dose after prolonged use (≥3 weeks) to avoid adrenal crisis. Morning dosing mimics cortisol rhythm and reduces insomnia. Monitor for hyperglycemia, osteoporosis, avascular necrosis, and immunosuppression. Do not give live vaccines during therapy.
ACTICORT (hydrocortisone/neomycin/polymyxin B) is a topical combination used for inflammatory ear conditions. Avoid prolonged use (>10 days) to prevent sensitization and overgrowth of non-susceptible organisms. Tympanic membrane perforation is a contraindication due to ototoxicity risk. Use the otic solution not the ophthalmic suspension for ear infections.
Take with food or milk to reduce stomach upset.,Do not stop abruptly; follow a tapering schedule from your doctor.,Notify your doctor if you experience fever, unusual bleeding, or weight gain.,Avoid live vaccines (e.g., MMR, nasal flu) while on prednisone.,Carry a steroid alert card or wear a medical ID bracelet.
Instill drops while lying down with affected ear upward, then remain in position for 5 minutes.,Do not touch dropper to ear or any surface to avoid contamination.,Complete full course even if symptoms improve; do not use longer than prescribed.,Report worsening redness, swelling, or hearing loss immediately.,Avoid getting water in ear during treatment; use a cotton ball soaked in petroleum jelly to protect ear when showering.
"The combination of Droxicam, a nonsteroidal anti-inflammatory drug (NSAID) with potent COX-1/COX-2 inhibition, and the corticosteroid Prednisone results in an additive risk of gastrointestinal (GI) mucosal injury and bleeding. NSAIDs suppress protective prostaglandin synthesis in the gastric mucosa via COX-1 inhibition, while corticosteroids further impair mucosal defense and repair mechanisms, increasing the likelihood of peptic ulceration, GI perforation, and hemorrhage. Patients, particularly the elderly or those with prior GI disease, face a significantly elevated risk of serious adverse outcomes including upper GI bleeding and perforation."
"Cabergoline, a dopamine receptor agonist, can cause valvular heart disease due to its agonistic activity at serotonin 5-HT2B receptors on cardiac valves, leading to fibrotic changes. Prednisone, a corticosteroid, may potentiate this risk by suppressing inflammatory responses that could otherwise mitigate fibrotic progression, and by inducing catabolic effects that may exacerbate tissue vulnerability. Concurrent use may therefore increase the severity and progression of valvulopathy and other fibrotic complications."
"Concomitant use of Suprofen, a nonsteroidal anti-inflammatory drug (NSAID), with Prednisone, a corticosteroid, increases the risk of gastrointestinal (GI) adverse effects, including ulceration, bleeding, and perforation. This additive effect results from synergistic inhibition of prostaglandin-mediated protective mechanisms in the gastric mucosa, as both drug classes suppress COX enzymes and reduce mucosal defense. Patients, especially the elderly or those with a history of peptic ulcer disease, are at heightened risk for serious GI complications."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PREDNISONE vs ACTICORT, answered by our medical review team.
PREDNISONE is a Corticosteroid that works by Agonist at glucocorticoid receptors, leading to altered gene transcription that results in anti-inflammatory and immunosuppressive effects, including suppression of cytokines, prostaglandins, and leukotrienes.. ACTICORT is a Corticosteroid that works by Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production and inflammatory mediators via glucocorticoid receptor binding.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PREDNISONE and ACTICORT depend on the specific clinical indication. These are both Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PREDNISONE is: 5-60 mg orally once daily or divided twice daily; for acute indications, initial dose 5-60 mg/day; for chronic conditions, lowest effective dose; route: oral, intravenous, intramuscular.. The standard adult dose of ACTICORT is: 5-60 mg orally once daily, or divided twice daily, depending on condition severity and response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PREDNISONE and ACTICORT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PREDNISONE is classified as Category D/X. First trimester: Increased risk of cleft lip/palate (odds ratio 1.3-3.4). Second/third trimester: Fetal growth restriction, adrenal suppression, preterm delivery. Chronic use: Dose. ACTICORT is classified as Category C. First trimester: Increased risk of cleft palate and cardiac defects (OR 1.3-3.5). Second/third trimesters: Risk of fetal growth restriction, adrenal suppression, and oligohydramnio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.